Inclusion Criteria:  Understood and signed an informed consent form; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Life expectancy >=3 months; Progressed after standard treatment or no standard treatment with an established survival benefit is available; Adequate organ/system function; Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped.  Exclusion Criteria:  Diagnosed and/or treated additional malignancy within 3 years before the first dose; With factors affecting oral medication; Toxicity that is >=Grade 2 caused by previous cancer therapy; Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before the first dose; Arterial thromboembolism and/or venous thromboembolism within 6 months; A history of psychotropic drug abuse or have a mental disorder; Any severe and/or uncontrolled disease; Has received surgery, chemotherapy, radiotherapy or other anticancer therapies 4 weeks before the first dose; Has received Chinese patent medicines with anti-tumor indications that National Medical Products Administration (NMPA) approved within 2 weeks before the first dose; Has received CDC7 inhibitors; Pleural effusion, pericardial effusion or ascites that cannot be controlled and need repeated drainage; Brain metastases ; Has participated in other clinical studies within 4 weeks before the first dose; According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.